Self-reported use, outcomes and adverse events of GLP-1 and research peptides on Reddit, 2026
Background: People now discuss and use not only approved incretin drugs (tirzepatide, semaglutide) but also retatrutide, which is still investigational, and unapproved "research peptides" such as BPC-157, TB-500, GHK-Cu and MOTS-c, often sourced outside regulated supply. These products sit outside routine safety monitoring. Methods: We analysed 3,092 public Reddit posts by 2,706 authors in 19 subreddits (7 June – 31 October 2026). A large language model (claude-haiku-4-5) coded each post against a fixed codebook for compounds, topic, self-reported outcome, duration, supply channel and adverse events (MedDRA-style terms). Coding was validated against a blind 250-post reference set (topic κ = 0.67, outcome κ = 0.61) and a blind pharmacist sample of 20 posts (adverse-event precision 0.81, recall 0.72). Posts by apparent minors were excluded. Results: 1,620 posts (52.4%) were first-hand reports. Among posts stating an outcome, the drug "worked" in 38.3% for tirzepatide, 31.0% for retatrutide and 23.7% for semaglutide; partial response was most common for all three. Nausea was the leading adverse event for the approved drugs (19.8% of first-hand semaglutide posts, 12.5% for tirzepatide). Retatrutide posts reported increased heart rate (3.7% vs 1.4%) and insomnia (4.4% vs 2.1%) more often than tirzepatide posts. Where a source was stated, 66.1% of retatrutide reports named a research-chemical supplier, against 8.7% for tirzepatide. Conclusions: Adverse-event profiles reported online match the trials for the approved drugs and show early signals for retatrutide, which is used largely outside regulated supply. Validated, AI-coded social listening can support safety monitoring before a drug is approved. Data: aggregate dataset at https://doi.org/10.5281/zenodo.24363468
Authors
- Marko Maal (ORCID: https://orcid.org/0009-0005-2578-8791)
Publication Details
- Journal
- Zenodo (CERN European Organization for Nuclear Research)
- Published
- 2026-11-19
- DOI
- https://doi.org/10.5281/zenodo.24363802
- Primary Topic
- Pharmacovigilance and Adverse Drug Reactions
- Type
- preprint